Swine Vaccines Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Swine Vaccines Market size will grow at 5.3% CAGR during 2024-2032, driven by the increasing prevalence of swine diseases. In 2023, data submitted to WOAH shows 315 new Foot-and-Mouth Disease outbreaks across 22 countries, with 80,292 cases and causing 1,194 direct deaths among a susceptible population of 1,771,382 animals. Diseases such as African Swine Fever and Classical Swine Fever not only impact the health of swine populations but also lead to substantial economic losses for producers due to decreased productivity and increased veterinary costs. As the frequency and severity of swine diseases rise, there is an accelerated demand for advanced vaccines that can effectively combat these health threats.

There is a significant investment in innovative vaccine technologies and improved disease management solutions. Research efforts are increasingly focused on developing more effective and targeted vaccines that address a wide range of swine diseases, including emerging and resistant strains. Advancements in biotechnology, genomics, and immunology are facilitating the creation of sophisticated vaccine formulations, enhancing their efficacy and safety profiles.

The swine vaccines industry is classified based on product, disease type, end-user, and region.

The mycoplasma hyopneumoniae segment will grow rapidly through 2032, as it has been a persistent challenge for swine producers worldwide. The vaccines targeting Mycoplasma Hyopneumoniae are specifically designed to induce an effective immune response, reducing the incidence and severity of the disease. As a result, producers are investing in these vaccines to ensure the well-being of their herds and to minimize the economic impact of this persistent pathogen.

The subunit vaccines segment will grow at a decent pace through 2032, as they offer a safer and more targeted approach compared to traditional vaccines. These vaccines are engineered to provide high efficacy with reduced risks of adverse reactions. They provide long-lasting immunity while minimizing the use of antibiotics, aligning with the industry's increasing focus on sustainable and ethical farming practices. The advancement in vaccine technologies, including the development of highly specific subunit vaccines, is expected to further enhance disease management in swine herds.

Europe swine vaccines industry will gain prominence through 2032, characterized by a strong emphasis on animal health and biosecurity, in consort with the European Union's stringent regulations on animal welfare and disease control. Additionally, the presence of leading vaccine manufacturers and research institutions in Europe contribute to the rapid development and availability of new vaccine products. A growing awareness among swine producers about the benefits of vaccination programs in improving herd health and productivity, is bolstering the regional market growth.

Product Code: 10445

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of swine diseases
  - 3.2.1.2 Growing consumption of pork
  - 3.2.1.3 Increasing government initiatives and support
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of vaccine development
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Inactivated vaccines
5.3 Live attenuated vaccines
5.4 Recombinant vaccines
5.5 Subunit vaccines
5.6 Toxoid vaccines
5.7 Other products

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Porcine reproductive and respiratory syndrome (PRRS)
6.3 Porcine circovirus type 2 (PCV2)
6.4 Mycoplasma hyopneumoniae
6.5 Classical swine fever (CSF)
6.6 Swine influenza
6.7 Erysipelas
6.8 Foot-and-Mouth disease (FMD)
6.9 African swine fever (ASF)
6.10 Porcine parvovirus
6.11 Other disease types

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Veterinary hospitals and clinics
7.3 Swine farms
7.4 Research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

9.1 Biogenesis Bago
9.2 Bioveta, a.s.
9.3 Boehringer Ingelheim International GmbH
9.4 Ceva Sante Animale
9.5 Elanco Animal Health Incorporated
9.6 HIPRA
9.7 Indian Immunologicals Limited
9.8 Merck and Co., Inc.
9.9 Phibro Animal Health Corporation
9.10 Vaxxinova
9.11 Virbac
9.12 Zoetis Inc.